IPP Bureau
EyeQ upgrades eye care facility in Surat
By IPP Bureau - February 18, 2025
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar
By IPP Bureau - February 18, 2025
Dr. Prabhavathi. R joins HEJJE
By IPP Bureau - February 18, 2025
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
ALPLA opens new manufacturing plant in Thailand
By IPP Bureau - February 17, 2025
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
By IPP Bureau - February 17, 2025
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
GSK’s Penmenvy approved by FDA to help protect against MenABCWY
By IPP Bureau - February 17, 2025
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
By IPP Bureau - February 17, 2025
No safety signals related to the vaccine candidate were identified
Nectar Life Care launches affordable anti-diabetic range of medicines
By IPP Bureau - February 17, 2025
Offers affordable, high-quality solutions for diabetes care
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
By IPP Bureau - February 15, 2025
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Imfinzi perioperative regimen improved survival across muscle-invasive bladder cancer patients
By IPP Bureau - February 15, 2025
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
By IPP Bureau - February 15, 2025
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Bayer files for approval of finerenone in heart failure in Japan
By IPP Bureau - February 15, 2025
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
By IPP Bureau - February 14, 2025
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Glenmark Pharmaceuticals USA launches Clindamycin Phosphate Foam, 1%
By IPP Bureau - February 14, 2025
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr
By IPP Bureau - February 14, 2025
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
